{
    "clinical_study": {
        "@rank": "89136", 
        "arm_group": {
            "arm_group_label": "Adult Gilomas"
        }, 
        "brief_summary": {
            "textblock": "The study will compare two different size MRI's of a brain tumor."
        }, 
        "brief_title": "High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Brain Tumor", 
        "condition_browse": {
            "mesh_term": "Brain Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The study is designed to directly compare the MR images of a brain tumor obtained on the 3T\n      and then 7T MRI in approximately 150 patients followed serially with MR imaging to evaluate\n      for tumor progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 18 years or older\n\n          -  Patient must meet at least one of the four following criteria regarding brain tumor\n             diagnosis:\n\n          -  Histological diagnosis of a brain tumor\n\n          -  Histological diagnosis of systemic cancer and brain MR imaging suggestive  of\n             metastatic disease to the brain\n\n          -  Pre-operative brain MR imaging suggestive of a brain tumor\n\n          -  Radiographic diagnosis of brain tumor in an inoperable location (e.g., brainstem)\n\n          -  Patient able and willing to provide informed consent\n\n          -  Karnofsky Performance status > 70%\n\n          -  Life expectancy greater than 3 months\n\n          -  Negative serum or urine pregnancy test or child bearing potential terminated by\n             surgery, radiation, menopause or current use of two approved methods of birth control\n\n          -  Patients who are excluded from 7T MR imaging because of titanium implants that are\n             not yet established to be safe at 7T remain eligible for the imaging at 3T * Spanish\n             speaking participants will be enrolled for this study\n\n        Exclusion Criteria:\n\n          -  Body weight >137 Kg (300 lbs)\n\n          -  Patient unable to provide informed consent\n\n          -  Karnofsky Performance status < 70%\n\n          -  Patients who are claustrophobic or have other contraindications to MRI, such as\n             implanted pacemaker device vascular clips, surgical clips, prosthetic valves,\n             pacemakers, otologic implants\n\n          -  NYHA class III and IV congestive heart failure\n\n          -  Psychiatric or addictive disorders that preclude obtaining informed consent\n\n          -  Unstable angina\n\n          -  Sexually active patients of childbearing potential not using a reliable contraceptive\n             method\n\n          -  Pregnant or lactating women\n\n          -  Women of childbearing potential who refuse a pregnancy test (performed during\n             screening)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients at the Simmons Cancer Center at UTSW"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035852", 
            "org_study_id": "062010-160", 
            "secondary_id": "1R01CA154843-01A1"
        }, 
        "intervention": {
            "arm_group_label": "Adult Gilomas", 
            "description": "3T MRI vs. 7T MRI", 
            "intervention_name": "MRI", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "UT Southwestern Medical Center"
            }, 
            "investigator": {
                "last_name": "Elizabeth Maher, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors", 
        "overall_contact": {
            "email": "sarah.mcneil@utsouthwestern.edu", 
            "last_name": "Sarah McNeil, RN", 
            "phone": "214-648-5573"
        }, 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "Elizabeth Maher, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Federal Government"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1. To determine the benefit of 7T MR imaging in brain tumor patients with regard to the improvement in resolution, as measured by the area of T2 FLAIR signal abnormality and the ability to detect abnormalities in vascular integrity. The benefit will be determined at a single time point as well as longitudinally for each patient at 6 month intervals.", 
            "measure": "Benefit of 7T MR imaging", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 month intervals after baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine if changes in vascular integrity at 7T can be correlated with tumor progression or transformation to high grade in patients with low grade gliomas.", 
            "measure": "Vascular Integrity", 
            "safety_issue": "No", 
            "time_frame": "Every 6 months, up to 12 months."
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}